血浆磷酸化Tau 217与Aβ42/40预测认知未受损者早期脑内Aβ积聚
该纵向研究纳入瑞典BioFINDER-2及两个独立队列(Knight ADRC、BioFINDER-1)的认知未受损参与者,评估基线血浆磷酸化Tau 217与Aβ42/40对基线Aβ低于40 Centiloids者后续脑Aβ积聚的预测价值。结果显示,血浆%p-tau217与Aβ42/40联合在检测脑脊液Aβ异常状态时曲线下面积为0.949(95%CI 0.929-0.970),且与基线及纵向Aβ-PET变化显著相关;p-tau231和GFAP未提供明确独立价值。
要点
- 血浆%p-tau217联合Aβ42/40检测脑脊液Aβ异常的AUC为0.949(95%CI 0.929-0.970),优于单个生物标志物。
- 基线Aβ-PET低于40 Centiloids者中,血浆%p-tau217与Aβ42/40和基线及纵向Aβ-PET变化显著相关。
- 血浆p-tau231和GFAP未提供明确独立预测价值。
核心结论
- 结果提示,联合血浆p-tau217与Aβ42/40水平可能有助于预测早期亚阈值Aβ积聚者的Aβ病理发展。
- 这些生物标志物可能因此有助于未来一级预防试验的参与者筛选。
研究设计与样本
- 纵向研究,纳入瑞典BioFINDER-2(入组2017-2022年)及两个独立复制队列Knight ADRC(入组1988年和2019年)和BioFINDER-1(入组2009-2015年)。
- 分析样本为认知未受损且基线有血浆p-tau217与Aβ42/40评估以及Aβ-PET或脑脊液Aβ42/40评估的便利样本。
- BioFINDER-2纳入495人,Knight ADRC纳入283人,BioFINDER-1纳入205人;BioFINDER-2平均(SD)年龄65.7(14.4)岁,女性261人(52.7%)。
- 数据分析时间为2023年4月至2024年5月。
主要发现
- 检测脑脊液Aβ异常状态时,血浆%p-tau217与Aβ42/40联合的AUC为0.949(95%CI 0.929-0.970;P<.02),优于单个生物标志物。
- 基线Aβ-PET低于40 Centiloids者中,基线血浆%p-tau217和Aβ42/40与基线Aβ-PET(n=384)及Aβ-PET随时间增加(n=224)显著相关。
- 联合两基线生物标志物模型中,与基线Aβ-PET的关联:%p-tau217 β=2.77(95%CI 1.84-3.70),Aβ42/40 β=-1.64(95%CI -2.53至-0.75),交互项β=-2.14(95%CI -2.79至-1.49),P<.001。
- 联合模型中与纵向Aβ-PET的关联:%p-tau217 β=0.67(95%CI 0.48-0.87),Aβ42/40 β=-0.33(95%CI -0.51至-0.15),交互项β=-0.31(95%CI -0.44至-0.18),P<.001。
- Knight ADRC中基线血浆%p-tau217(β=0.71;95%CI 0.26-1.16;P=.002)和Aβ42/40(β=-0.74;95%CI -1.26至-0.22;P=.006)与纵向Aβ-PET独立相关;BioFINDER-1中p-tau217(β=-0.0003;95%CI -0.0004至-0.0001;P=.01)和Aβ42/40(β=0.0004;95%CI 0.0002-0.0006;P<.001)与纵向脑脊液Aβ42/40独立相关。
关键数值与推荐
- 基线亚阈值脑Aβ水平定义为Aβ水平<40 Centiloids。
- 检测脑脊液Aβ异常状态时,血浆%p-tau217与Aβ42/40联合的AUC为0.949(95%CI 0.929-0.970;P<.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Phase 3 trials of successful antiamyloid therapies in Alzheimer disease (AD) have demonstrated improved clinical efficacy in people with less severe disease. Plasma biomarkers will be essential for efficient screening of participants in future primary prevention clinical trials testing antiamyloid therapies in cognitively unimpaired (CU) individuals with initially low brain β-amyloid (Aβ) levels who are at high risk of accumulating Aβ. OBJECTIVE: To investigate if combining plasma biomarkers could be useful in predicting subsequent development of Aβ pathology in CU individuals with subthreshold brain Aβ levels (defined as Aβ levels <40 Centiloids) at baseline. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal study including Swedish BioFINDER-2 (enrollment 2017-2022) and replication in 2 independent cohorts, the Knight Alzheimer Disease Research Center (Knight ADRC; enrollment 1988 and 2019) and Swedish BioFINDER-1 (enrollment 2009-2015). Included for analysis was a convenience sample of CU individuals with baseline plasma phosphorylated tau 217 (p-tau217) and Aβ42/40 assessments and Aβ assessments with positron emission tomography (Aβ-PET) or cerebrospinal fluid (CSF) Aβ42/40. Data were analyzed between April 2023 and May 2024. EXPOSURES: Baseline plasma levels of Aβ42/40, p-tau217, the ratio of p-tau217 to nonphosphorylated tau (%p-tau217), p-tau231, and glial fibrillary acidic protein (GFAP). MAIN OUTCOMES AND MEASURES: Cross-sectional and longitudinal PET and CSF measures of brain Aβ pathology. RESULTS: This study included 495 (BioFINDER-2), 283 (Knight ADRC), and 205 (BioFINDER-1) CU participants. In BioFINDER-2, the mean (SD) age was 65.7 (14.4) with 261 females (52.7%). When detecting abnormal CSF Aβ-status, a combination of plasma %p-tau217 and Aβ42/40 showed better performance (area under the curve = 0.949; 95% CI, 0.929-0.970; P <.02) than individual biomarkers. In CU participants with subthreshold baseline Aβ-PET, baseline plasma %p-tau217 and Aβ42/40 levels were significantly associated with baseline Aβ-PET (n = 384) and increases in Aβ-PET over time (n = 224). Associations of plasma %p-tau217 and Aβ42/40 and their interaction with baseline Aβ-PET (%p-tau217: β = 2.77; 95% CI, 1.84-3.70; Aβ42/40: β = -1.64; 95% CI, -2.53 to -0.75; %p-tau217 × Aβ42/40: β = -2.14; 95% CI, -2.79 to -1.49; P < .001) and longitudinal Aβ-PET (%p-tau217: β = 0.67; 95% CI, 0.48-0.87; Aβ42/40: β = -0.33; 95% CI, -0.51 to -0.15; %p-tau217 × Aβ42/40: β = -0.31; 95% CI, -0.44 to -0.18; P < .001) were also significant in the models combining the 2 baseline biomarkers as predictors. Similarly, baseline plasma p-tau217 and Aβ42/40 were independently associated with longitudinal Aβ-PET in Knight ADRC (%p-tau217: β = 0.71; 95% CI, 0.26-1.16; P = .002; Aβ42/40: β = -0.74; 95% CI, -1.26 to -0.22; P = .006) and longitudinal CSF Aβ42/40 in BioFINDER-1 (p-tau217: β = -0.0003; 95% CI, -0.0004 to -0.0001; P = .01; Aβ42/40: β = 0.0004; 95% CI, 0.0002-0.0006; P < .001) in CU participants with subthreshold Aβ levels at baseline. Plasma p-tau231 and GFAP did not provide any clear independent value. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that combining plasma p-tau217and Aβ42/40 levels could be useful for predicting development of Aβ pathology in people with early stages of subthreshold Aβ accumulation. These biomarkers might thus facilitate screening of participants for future primary prevention trials.
引用
- Janelidze S, Barthélemy NR, Salvadó G, et al. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment. JAMA Neurol. 2024. PMID: 39068669. doi:10.1001/jamaneurol.2024.2619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。